• The company’s current independent pharmacy member base represents over 50% of the United States pharmaceutical market within that vertical
• Actively used in all 50 states with over 11,700 pharmacies in its network, serving around 15 million patients indirectly through these networks of pharmacies

Pharmaceutical supplies and services provider Trxade Group (NASDAQ: MEDS) benefited from an increased exposure to potential investors in September, by attending several virtual investor events and conferences, where it was given the opportunity to present its innovative platform and its advantages for pharmacy members.

The company started the last month of the third fiscal quarter strong by attending the LD 500 Virtual Investor Conference, held September 1-4. During a presentation on September 2, Trxade CEO Suren Ajjarapu focused on the company’s prescription affordability efforts and its commitment to helping pharmacies met their customers’ needs while remaining profitable.

Following the LD Micro event, Trxade attended the 2020 Colliers Institutional Investor Conference on September 10 and the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16. Mr. Ajjarapu was available for one-on-one meetings during both events and hosted a virtual presentation during the Wainwright convention on September 16.

Such investor events can help Trxade further raise the profile of its supply chain trading platform that offers independent pharmacies nationwide access to the best supplier prices for prescription drugs. Currently, the company has an established presence in all 50 states, with over 11,700 pharmacies in its network. The company is indirectly serving around 15 million patients via these independent pharmacies within its network, according to Ajjarapu. Through the trading platform, independent pharmacies can see “up-to-the-minute” supply and pricing for pharmaceutical needs on a cost-efficient basis.

The Trxade Marketplace Platform uses a proprietary database and algorithms to identify pharmaceuticals likely to be in short supply. These are then delivered to independent pharmacies. The pharmacy’s total annual purchase costs can be reduced by up to 7-10%. No membership or transaction fees are required of them and they gain the ability to off-set negative insurance reimbursements.  The safe, secure, and easy web platform instantly connects to thousands of pharmacies with real-time information.

Integra Pharma Solutions is another Trxade division. Providing quality Rx products with significant savings, Integra Pharma Solutions is a pharmaceutical supplier for healthcare organizations of all sizes. Current healthcare markets serviced via Trxade include Government organizations, hospitals, independent pharmacies, and clinics across the nation. Trxade so far has over $800K+ in awards from the US Department of Veterans Affairs, 23K+ SKUs representing hundreds of manufacturers’ products, 60+ supply partners.

The company’s B2C operations are led via Bonum Health, which provides 24/7 access to Board-Certified Providers and Health Assessment Tools at a time when telehealth services are in high demand. Smart technology allows doctors and specialty providers to view vitals through special integrations like FitBit, iHealth, etc. Pending the outcomes of pilot programs, the company expects to make Bonum Health available nationwide.

Providing the sale of products directly to consumers, Trxade’s Community Specialty Pharmacy handles specialized care for patients suffering from chronic conditions. The focus is on rare or difficult to find medicines, including self-injectables, oral, and other supportive therapies.

This business model is proving beneficial for Trxade. At the end of Q2, the company showcased a 244% increase in revenue and a 74% increase in gross profit. Most of the growth can be attributed to an increase in sale and distribution of personal protective equipment (“PPE”) like N95 masks and sanitizing products, in response to the COVID-19 pandemic, through the Integra Pharma unit. When comparing numbers from June 30, 2020, against June 30, 2019, revenue increased from $5.6 million to $12.8million (“TTM”). Gross profits increased from $4.0 million to $6.2 million.

The main drivers of Trxade Group’s growth strategy are to increase the number of independent pharmacies serviced, increase the number of purchases per pharmacy, and increase the average amount of money spent per pharmacy.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Electric vehicles represent the next frontier of vehicular travel. Thanks to powerful battery packs, electric vehicles run on clean energy and produce minimal to zero emissions, making them the perfect vehicle for customers who are conscious of their carbon footprints. For customers who switch from carbon powered vehicles, especially those who’ve used conventional vehicles for years, taking a crash course on EV batteries and charging is crucial.

Unlike traditional vehicles that run on carbon fuel, electric vehicles are powered by rechargeable lithium-ion battery packs. To refuel a carbon fuel-powered vehicle, all you need to do is head to a gas station and fill the gas tank with as much fuel as you want. It’s a little different for electric vehicles, however. As an EV driver, you will have to rely on a network of charging stations and many choose to have a specialized EV charger installed at their home.

The amount of time it takes to charge the vehicle will depend on the size of its battery pack (let’s use a hypothetical EV with a 50kWh battery) as well as how fast the electric current is being delivered. There are three main types of charging speed: slow, rapid, and fast.

Slow charging, as the name suggests, is the slowest type of charging at around 2.3kW to 3 kW. Household sockets fall into this category, and they charge EVs super slow, taking around 22 hours to fill up a 50kWh EV. Clearly, not the best option if you are in a hurry. However, slow charging may conserve battery life as less heat is produced as a byproduct of internal resistance compared to faster charging.

Fast charging is the most commonly used by EV users. A fast charger will release juice at 7kW or 11kW if you’re using a Tesla Destination charger. A 50kWh electric vehicle would take roughly 8 hours to charge up. Considering that most EVs spend this amount of time parked at home overnight or at work during the day, fast charging is considered by many EV drivers to be the most ideal charging speed.

Rapid charging has been getting a lot of attention recently. Typically found at motorway service stations or on main driving routes, rapid chargers can fill your car up within minutes. A 50kW DC fast charger, common around Europe and North America, can get a 50kWh EV to 80% in around 45 minutes. Ultra-rapid chargers, like Tesla’s Supercharging network, can get an EV from 20% power to 89% within 20 minutes.

However, rapid charging has the potential to degrade your battery pack and ultimately reduce its lifespan. It also tends to be more expensive than slow and fast charging. Ultimately, the charging speed you use will depend on your needs and how much you are willing to part with. Undoubtedly, companies like Net Element (NASDAQ: NETE) would gladly work with EV makers to develop payments solutions for battery pack charging facilities.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Up until now, we have only seen scientists linking the brain to a monitor in sci-fi movies where the evil scientist wants to manipulate the subject’s brain or fry it to pudding. This is now a near-reality after a team of neuroscientists and engineers from the St. Petersburg State University in Russia, Technische Universität Dresden in Germany and University of Sheffield in the UK used the power of 3D printing to improve neural implant technology. The study has been published in Nature Biomedical Engineering.

The team was led by Professor Pavel Musienko from St. Petersburg and Professor Ivan Minev, from the Department of Automatic Control and Systems Engineering at the University of Sheffield. The two developed a neural implant prototype that can be utilized in the development of treatments for issues that plague the nervous system.

The neural implant has previously been utilized in the stimulation of spinal cords of animal models suffering from spinal cord injuries. Now they can also be used to create new treatments for humans who suffer from paralysis. The study shows how the implant fits on the brain’s surface, the peripheral muscles and nerves and the spinal cord. This has opened up a slew of possibilities of its implementation in other neurological disorders.

For many researchers in the worlds of technology, science and medicine, linking the brain through the use of a neural interface to a computer is a goal they would like to achieve. Despite the efforts being made to make this a reality, the innovation field is held back by the lengthy development periods and hefty costs that go into building prototypes.

However, the technology shows huge potential in bringing new treatments for injuries that affect the nervous system, all based on a fusion of electronics and biology. The researchers expect the neural implants to sense and issue small electrical impulses to the nervous system and the brain.

Using 3D printing, the team has demonstrated how prototype implants can be made in a cost effective and quicker way, which will accelerate development and research in that area. Additionally, the implants can be modified easily to target a specific problem or area in the nervous system.

Professor Ivan Minev stated that the research which began at Technische Universität, Germany and continued at the University of Sheffield has shown how 3D orienting can be used to create implant prototypes at a cost and speed that had not previously been done while still keeping the standards that are needed to produce a useful tool. The team has also demonstrated how 3D printers can develop implants that can liaise with the nerves and the brain.

Minev adds that in the future, the implant may be modified to fit a clinical need in patients, with it being printed in the OR as the patient is prepared to go under the knife. Industry watchers say such technology could open up immense possibilities for biomed sector players like DarioHealth Corp. (NASDAQ: DRIO).

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

For many years, the most popular and well known cannabinoid was THC. However, in the recent times, there has been an increase in CBD awareness and popularity.

Search trends on Google indicate that CBD is searched more often as compared to THC, and this has been the case for the last few years. Clearly, interest in CBD is on the rise, but is its use increasing too? Many wonder if CBD products will lead to a decline in THC popularity among patients and consumers. Will that be the case? Below are some reasons why CBD might just eclipse THC in the consumption department.

CBD products are easier to cultivate

CBD products are also referred to as low-THC products. Marijuana strains that are low in THC are more common in nature than strains that are high in THC. To get a plant to yield high amounts of THC, you require the right ecosystem and environment.

This is in comparison to hemp with low THC which can grow anywhere, as long as the temperatures are not extremely cold or hot. Additionally, low THC products can be locally sourced, making them easier to get to international markets.

This makes low THC varieties of marijuana easier to cultivate unlike high THC varieties, which boosts their popularity with consumers.

There are more favorable laws governing CBD

Most low-THC products that are internationally available are derived from hemp and in many countries, the regulations and laws of hemp are generally more favorable as compared to non-hemp cannabis varieties. A great example of a country with favorable laws would be Switzerland.

In Switzerland, floral hemp or low-THC marijuana, is very popular and widely available for legal purchase by adults. While products that have more than 1% THC in them are prohibited for recreational use, marijuana products that have less than 1% THC are legal in the country.

History has shown that a country is less likely to pass a high-THC recreational law but will have no qualms with approving a low-THC medical marijuana law. This also affects consumer popularity.

Reduces the use of prescription medication

A recent study discovered that the increased availability of low-THC marijuana products led to a decrease in the use of pharmaceutical drugs. This is not only good for marijuana consumers but also for the society as a whole, as there’s a decrease in public-entitlement health-related costs.

This just goes to show that as the fight to have plant-based therapies recognized as an alternative form of treatment, many are finding ways to incorporate low-THC marijuana remedies into their routines, showing that there is a growing trend of these products capturing a bigger market share. What do companies like The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) think about this growing trend?

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Researchers have discovered that coronavirus patients who were hospitalized and had vitamin D sufficiency were at a significantly lower risk of experiencing hypoxia, becoming unconscious or dying. Additionally, they had high levels of lymphocytes, which are immune cells that help the body fight infections, and had low levels of the C-reactive protein, which is an inflammatory marker.

The study was authored by Michael F. Holick, who is a professor of physiology, medicine and molecular medicine and biophysics at Boston University School of Medicine. The professor explained that the study provided evidence showing that sufficient levels of vitamin D reduced COVID-19 complications, such as the release of too many cytokines into the patient’s blood rapidly (cytokine storm) and death.

The study involved 235 patients admitted to the hospital with coronavirus from whom blood samples were collected. The samples were used to measure the vitamin D levels of the patients as well as analyze lymphocyte numbers and C-reactive protein.  The patients were then observed for any developments in their symptoms such as unconsciousness, and difficulty breathing that caused hypoxia and ultimately, death. The scientists then compared this data in patients who had sufficient vitamin D levels to those that suffered from its deficiency.

In patients who were more than 40 years old and vitamin D sufficient, the researchers found that they were 51.5% less likely to die from an infection in comparison with the patients who were vitamin D insufficient or deficient.

In another study that was recently published by Holick, they discovered that being vitamin D sufficient can decrease the contraction risk of COVID-19 by 54%. The researchers also believe that having vitamin D sufficiency can help the body fight the coronavirus as well as other viruses that cause upper respiratory tract infections, such as influenza. He added that there was still concern that the fusion of a coronavirus infection and an influenza infection may increase hospitalizations considerably as well as death, which may occur as a result of adverse effects from these viral infections.

Holick states that the study gives a cost-effective and simple plan to improve an individual’s ability to fight COVID-19 and decrease the coronavirus’ adverse outcomes like a patient being hooked up to a ventilator or an immune response that leads to a cytokine storm or death. Furthermore, he adds that it’s only prudent for individuals to take vitamin D supplements, especially since vitamin D insufficiency and deficiency is so common among both adults and children. This, he says, may help decrease the risk of infection or experiencing complications from the coronavirus.

This discovery that vitamin D levels can affect the extent to which one is affected by COVID-19 may be of interest to biomedical entities like Predictive Oncology (NASDAQ: POAI) since it strengthens the hypothesis that nearly all disease conditions are linked to a nutritional deficiency.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Researchers from Johns Hopkins University have discovered that septic shock can be classified into four categories, making it easier for hospitals to accurately triage sepsis patients and treat individuals who are at higher risk first. This will prevent a higher mortality rate from people dying due to this costly and deadly medical condition.

The leading causes of in-hospital deaths are septic shock and sepsis. Biomedical researchers from the Johns Hopkins School of Medicine and Whiting School of Engineering state that their findings may be used to detect early signs of septic shock in patients who are rapidly developing the infection as it overpowers their immune system. Septic shock in fatal cases can lead to organ failure and eventually, death.

This new study from the Institute of Computational Medicine and the Department of Biomedical Engineering also shows that septic shock starts much earlier than health practitioners currently understand. The findings from the study will help in answering a lot of the questions that surround this deadly disease, although we may have to wait a bit longer for an algorithmic definition to be discovered.

The lead author of the study and doctoral student in biomedical engineering, Ran Liu, said that they used patients’ risk categories to group them. This demonstrated the usefulness of having various risk categories that would indicate the severity of septic shock cases in patients. Their research was supervised by Raimond L. Winslow, who is Liu’s adviser and also the director of the Institute for Computational Medicine. Additionally, the research was published on eLife.

The study, which used more than 24 physiological indicators, collected from 200,000 individual admissions from various hospitals in the U.S., discovered that the increase in risk of an individual to suffer from septic shock occurred within half an hour to an hour after the first sign of shock registers.

The descent into septic shock registers as rapid shifts in lactate levels, heart rate and blood pressure. When a patient’s immune system is overpowered by an infection, the body starts to lose the ability to stop the body from deteriorating further. The scientists believe that this is when septic shock begins and refer to this period as “pre-shock.”

The study states that when a patient enters the pre-shock stage, they are already in a state of septic shock. Patients who have been categorized in the highest risk of experiencing septic shock are in a septic shock stage for at least 10 hours before they can satisfy what is the current clinical definition of septic shock.

The paper adds that the plummet into pre-shock is quite rapid and that the use of intelligent and automated monitors may help detect it in patients. The researchers recommend that hospitals begin implementing automated technology to help detect these early warnings. Furthermore, the study supports the existing research that requires lactate measurements be done every 1- 2 hours for better categorization of patients, stating that their research calculates median time between lactate observations to be 11.2 hours.

Septic shock is a serious condition, and there is no doubt that biomed companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) welcome the additional information that this research has unveiled about this condition.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• SRAX recently closed acquisition of LD Micro, leading micro-cap information portal
• LD Micro to become wholly-owned subsidiary of SRAX for 1.6 million in common stock plus $4 million cash
• Acquisition to accelerate adoption of Sequire, SRAX’s SaaS investment analytics platform
• Sequire revenue grew 29% year-over-year for Q2 2020, user base doubled to one million users during Q3 2020

SRAX (NASDAQ: SRAX), a data-based financial technology company, recently closed the acquisition of LD Micro, a leading data portal serving the small and micro-cap space. The deal, worth 1,600,000 shares of common stock and $4 million in cash, will make LD Micro a wholly-owned subsidiary of SRAX while maintaining founder Christopher Lahiji as president and appointing him to SRAX’s board of directors.

The move comes during a rapid growth period for Sequire, SRAX’s data analytics SaaS platform. Geared towards the investment industry, Sequire unlocks data and insight for public companies that can be used to activate marketing campaigns to engage both new, existing and potential investors.

Prior to acquiring LD Micro, SRAX had witnessed strong early success with Sequire. The platform doubled its user base to over one million investors and traders in two months (http://nnw.fm/JRZtk), in addition to posting Q2 earnings that showed a 29% increase in year-over-year revenue. The acquisition of LD Micro – a leading brand in the provision of exclusive information on micro-cap North American stocks – is expected to accelerate the adoption of Sequire while enhancing LD Micro’s own digital assets.

Sequire helps public companies gain insights on the activities of both retail and institutional investors, providing critical actionable data to activate successful campaigns aimed to increase engagement with current investors while attracting new ones. Sequire’s application suite is currently being used by over 91 companies to harness the power of their data through the use of tools that leverage investor intelligence and outreach, track warrants, engage users through surveys, and promote events and roadshows.

“The platform is an absolute game-changer for public companies and their shareholders,” said LD Micro founder Chris Lahiji in recent statements  (http://nnw.fm/ppRfl). “Both companies believe that one day executives will rely on Sequire the same way investors rely on Bloomberg.”

“Over 1,500 companies have presented at LD Micro’s events since 2008, and almost all of them would be immediate beneficiaries of this technology,” he continued.

The acquisition of LD Micro is expected to be immediately accreditive to SRAX’s operations. The recent LD 500 conference, held online in early September, included presentations from hundreds of companies across a wide range of industries in addition to featuring keynotes with some of the most prominent figures in the micro-cap world.

The company continues to leverage the growing demand for quantifiable and detailed consumer data by creating specialized tools that empower companies to reveal core consumers and their characteristics across a wide range of industries.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients
• Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients
• POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid clinical decision-making and lead to better health outcomes. The National Cancer Institute (“NCI”) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of AI in developing oncological treatments (https://ibn.fm/BFD5m) – a niche where Predictive Oncology is increasingly building a dominant presence. In addition, the White House has announced $2 billion funding for public and private sector “AI hubs” designed to drive key advances in AI as well as other computational technologies (https://ibn.fm/kcgSH).

A primary goal of precision cancer medicine is the accurate prediction of optimal drug therapies based upon the personalized molecular profiles of patient tumors; ideally, such predictions are based upon well-established molecular cause-and-effect relationships that are disrupted in cancer calls (https://ibn.fm/LQvQX). The foundation of these accurate predictions is built upon extensive bodies of data, with the volume of cancer-relevant data being generated and electronically stored on a daily basis vastly exceeding what could even be imagined only a few decades ago. As such, the search for significant correlations within cancer-relevant “big” datasets is a task which is ideally suited for artificial intelligence and machine learning-based approaches.

Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its unique real-world longitudinal data of drug-response and genomic profiles gathered from more than 150,000 de-identified cancer cases. Through its subsidiary Helomics, POAI is seeking to bring this cutting-edge technology to cancer research, where it is working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors respond to drugs, which can be used both for clinical decision support and research into new therapies.

Meanwhile, the company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ proprietary Oncology Capture Technology Platform, which is able to grow the patient’s heterogeneous tumor sample in the laboratory, enabling oncologists to develop a patient-specific treatment plan (https://ibn.fm/byGJI).

Going forward, the use of artificial intelligence will help oncological researchers quickly understand how cancer cells become resistant to anti-cancer drugs, which can help improve drug development and adjust drug use. The technology can also be used to manage the use of chemotherapy drugs and predict a patient’s tolerance levels, thus allowing for chemotherapy regimens to be optimized. In the future, by leveraging Predictive Oncology’s AI-driven solutions, doctors will be able to make better-informed treatment decisions, thus reducing the need for unnecessary or poorly targeted treatments and improving patient outcomes.

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

It’s becoming increasingly difficult to bury our heads in the sand in regard to climate change. The earth is hurtling towards a ‘hothouse’ state not seen in 50 million years and a lot of the blame lies at the feet of humanity. Perhaps the most obvious sign of climate change is that it’s getting hotter and according to scientists, the next three years might be even hotter than normal. No state has experienced the heat as much as California; five of the largest wildfires in state history have been ignited in recent weeks, and residents have become accustomed to rolling blackouts due to heat waves.

In a bid to reduce their carbon footprint, plenty of governments have launched programs to phase out internal combustion-engine vehicles in exchange for electric vehicles (“EVs”) that run on clean, renewable energy and produce zero emissions. Similarly, California Governor Gavin Newsom has already set the goal of 100% zero-emission energy sources for the state’s electricity by 2045. He signed the bill mandating the electricity target in 2018 as well as an executive order calling for statewide carbon neutrality.

His latest effort at reducing greenhouse gas emissions came on Wednesday when Newsom pledged to ban all sales of new gasoline-powered vehicles by 2035. The order won’t prevent Californians from owning or selling gasoline or diesel-powered vehicles on the used-vehicle market, rather it will prevent the sale of new carbon energy-powered vehicles. This pledge makes California the first state in the country to ban conventional vehicles alongside 15 other countries including France and Germany.

The move was met with resistance from White House spokesman Judd Deere who claimed it was another example of “how extreme the left has become,” concluding that “the lengths to which they will go to destroy jobs and raise costs for the consumer is alarming.” However, Governor Newsom disagrees, arguing that the Trump administration’s argument is “stale” and inaccurate. “This is where the automobile manufacturers are going,” he says. “We want to accelerate a trend you’re seeing all around the rest of the world.”

He states that the plan is absolutely doable based on the state’s infrastructure. “We can do it. I mean, the reality is we’re already doing it. Thirty-four percent of our electricity comes from renewable places. We have over 50% of all the electricity produced and procured in California from non-carbon sources. We have a plan. We have a strategy,” he says. On the Trump administration’s claim that switching to green energy will devastate the job economy, Newsom says that it is not factual.

“It’s gobbledygook. It’s nonsense. It’s not factual. It’s not even an interesting argument. It’s rather stale. Already, California has five times more green jobs than we do fossil fuel jobs. Fossil fuels are really the alternative energy.”

Analysts say such steadfastness as displayed by Gov. Newsom attracts the admiration of companies like Net Element (NASDAQ: NETE) that would like carbon emissions to be brought to a halt in all major economies and around the world.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Three scientists from Johns Hopkins; a biomedical engineer, a pharmacologist and a biophysicist, have come together to build a device that can detect if an individual has SARS-CoV-2 antibodies, which is the virus that causes COVID-19. Antibodies are small proteins produced by the immune system to help your body counteract a viral encounter and provide the immunity to fight it off if future infections occur.

The researchers derived their inspiration from a glucose monitor, which is used by millions of people around the world. This, they said, could help them design an antibody detector that can be used easily and is affordable worldwide.

People who suffer from diabetes use glucose monitors to measure their blood sugar levels. This is done by pricking their finger for a drop of blood which is then placed on a test strip paper and inserted into the monitor.

The three researchers; Jamie Spangler, assistant professor of biomedical engineering, Netz Arroyo, assistant professor of pharmacology and molecular sciences, Taekjip Ha, professor of biophysics, biophysical chemistry and biomedical engineering say that this gadget can also be re-engineered to detect the presence of glucose in chemical reactions that occur as a result of antibodies in the blood.

To do this, the team developed a test strip which contained spike protein obtained from the SARS-CoV-2 virus surface. Then they added a drop of blood from a patient and observed as the COVID-19 antibodies that were present in the blood bind with the spike proteins on the test strip. After this, the scientists dipped the test strip into a tube which contains an enzyme that binds itself to the coronavirus antibodies.

The next step was to wash off the excess enzyme and insert the strip into a solution that contained a molecule that the enzyme transforms into glucose. Finally, they used a glucose monitor to read the amount of glucose that is present on the strip, which is a substitute for coronavirus antibodies present in the blood sample from the patient.

Arroyo stated that working on the project had been a good opportunity to learn from his colleagues, engage with them and brainstorm together to generate a creative solution that addressed a crucial need that was brought forth by the coronavirus pandemic. He added that they were looking into developing a bio sensing platform that would help monitor infection spread better for both the current crisis as well as for any that might occur in the future.

The research is still ongoing, and the scientists are running more tests on the patent-pending technology. Analysts say biomed sector players like DarioHealth Corp. (NASDAQ: DRIO) are pleased so many innovators rising up to the challenge of the ongoing pandemic.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020
• CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers
• Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members, Dr. Waldemar Priebe, Ph.D., and Dr. Sigmund Hsu, M.D., both of whom were involved in the Phase 1 trial of Berubicin, CNS Pharmaceuticals’ lead drug candidate.

Dr. Wen is a Neurology professor at Harvard Medical School and the Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute. Dr. Wen is a member of the Board of Directors of The Society for Neuro-Oncology and is also its immediate past President. An accomplished neuro-oncologist with a proven track record treating brain tumors and related neurologic complications, Dr. Wen is a graduate of University of London’s Medical College of St. Bartholomew’s Hospital. He continued his postgraduate internal medicine training with the University of London and completed his neurology residency with the Harvard-Longwood Neurology Training Program.

According to CNS Pharmaceuticals CEO John Climaco, Dr. Wen’s extensive experience in neuro-oncology will be invaluable to the company as it prepares for its upcoming Berubicin clinical trials. “The addition of Dr. Wen strongly complements our strategy to further drive the development of Berubicin as we look forward to initiating our pivotal Phase II trial in the U.S. and to working with our partner WPD Pharmaceuticals on the Phase I pediatric and Phase II adult studies in Poland,” Climaco added.

Dr. Wen’s appointment was included among the latest company updates furnished to the Securities and Exchange Commission on September 21, 2020. The investor presentation in the Form 8-K/A also announced that the company’s pivotal Phase 2 clinical trial for Berubicin in the United States is expected to begin in Q1 2021 (https://ibn.fm/MRaIq). In addition, Berubicin clinical trials in Poland (Phase 2 for adults and the first-ever Phase 1 trial for pediatric patients) are also due to begin on a similar timeline.

CNS Pharmaceuticals’ lead drug candidate is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. It is an organ targeted therapeutic that belongs to a class of cancer drugs called anthracyclines. CNS Pharmaceuticals has stated that it believes, based on limited clinical data, that Berubicin is the first drug in this class to cross the blood-brain barrier in adults, reaching the tumor cells of a patient with brain cancer.

Berubicin was developed by CNS Founder and Scientific Advisory Board member Dr. Waldemar Priebe, Ph.D., Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. The development of Berubicin has been ongoing for over 15 years. The drug was granted Orphan Drug designation by the FDA for malignant gliomas in June 2020. CNS Pharmaceuticals is currently expected to make an Investigational New Drug (“IND”) submission to the FDA in Q4 2020.

In Phase 1 trials of Berubicin, conducted by Reata Pharmaceuticals (NASDAQ: RETA), 44% of GBM patients showed clinically significant response to Berubicin. A patient from the Phase 1 trial remains cancer-free following the trial treatment of Berubicin approximately 14 years ago.

CNS Pharmaceuticals plans for the Phase 2 adult trial in the United States to be adaptive, randomized, and controlled. These criteria for Phase 2 are intended to provide the data required for accelerated approval by the FDA. Additionally, the company plans to use the Phase 2 adult trial in Poland, conducted by sub-licensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1), to provide additional statistical support for the U.S. trial.

Plans are also in motion to begin Berubicin clinical trials for lymphomas, pancreatic, and ovarian cancers in 2021, which speaks to the high level of confidence CNS Pharmaceuticals has in Berubicin trials and its potential impact on the brain tumor therapeutics market. It is estimated that the global brain tumor therapeutics market will reach $3.4 billion by 2025, growing at a CAGR of 7.2 percent (https://ibn.fm/qJSuy).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

A proposal to legalize cannabis sales in Vermont and another one that provides automatic expungements for marijuana convictions have been pushed to the governor’s desk after a final Senate vote was conducted on Tuesday.

The state Senate approved the negotiated legislation with a 23-6 vote after the House of Representatives had approved it.

In 2018, Vermont legalized the cultivation of 2 marijuana plants and possession of a maximum of 29 grams of marijuana. However, no regulations that allow retail sales were put in place.

The governor of Vermont, Gov. Philip Brian Scott (R) has yet to explicitly confirm or deny whether he will put his signature on the S.54 measure but he admitted to being impressed last week on how the measure was received in the legislative process and noted that he would take that into account.

Apart from the marijuana sales legalization bill, the Senate also approved a separate bill that will issue automatic expungements of cannabis convictions as well as allow individuals to possess and grow more marijuana without being arrested. The House had passed the proposal earlier this month, meaning it’s also headed to the governor’s desk as well.

The proposed marijuana sales bill states that cannabis would be subject to the state’s 6% sales tax and an additional 14% excise tax. S.54 also highlights a few social equity provisions like helping individuals who have been adversely affected by the drug war and making cannabis business licenses for minorities a priority. Additionally, an independent regulatory commission will be in charge of promoting small business participation in the market.

A cannabis control commission would be established and would be responsible for the issuance of licenses to growers, retailers, manufacturers, labs and wholesalers. This body will also assume the role of the Department of Public Safety in regulating the state’s medical marijuana industry.

Additionally, flavored vape cartridges would be banned and a 30% THC limit would be imposed on marijuana flower while marijuana oil may only contain at most 60% THC.

A fiscal analysis that was done on the final bill shows that Vermont will generate roughly $13.3 million – $24.2 million in annual marijuana tax revenue by the Fiscal Year 2025. The Joint Fiscal Office estimates that licensing fees may generate an additional $650,000 in revenue each year. Municipalities that have cannabis businesses will also be allowed to impose additional local fees.

Industry watchers say sector players like The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) will be hoping that the governor puts the wishes of the people into consideration while deciding whether to enact or reject the marijuana policy reform bills before him.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Researchers from Georgia Tech, Harvard Medical School and the Boston Medical Center have developed a new online learning-based tool that allows the health sector to detect coronavirus outbreaks earlier in various counties in the U.S.

The Coronavirus outbreak detection tool is usually updated 2-3 times every week. It forecasts how fast a coronavirus outbreak will spread in a county by approximating the doubling rate of cases. The doubling time refers to the total number of days it takes for the cases in any given county to double. The tool takes into consideration the reported coronavirus deaths and cases, social distancing measures, face masks mandates, the rates of positive tests, changes in tests performed as well as the CDC’s Social Vulnerability Index.

This generates an interactive map that lets the users see a specific county’s population, the total number of new coronavirus cases in the county in the last week, the average number of cases recorded every day in the last week and also the coronavirus doubling rate.

Turgay Ayer, who is an associate professor in Georgia Tech H. Milton Stewart School of Industrial and Systems Engineering, says that it is important to identify an outbreak promptly to ensure that the area in question can be isolated. This will in turn help limit the spread to neighboring locations, and this will in turn assist in effectively containing the pandemic. The tool provides an upper hand in early detection of an outbreak as it is automated, thus speeding up the process.

An assistant professor at Harvard Medical School who is also the associate director at the Massachusetts General Hospital Institute for Technology Assessment, Jagpreet Chhatwal, states that while the earlier measures focused on reducing the spread of COVID-19 at the state level, detecting outbreaks at a local level allows the legislators to execute the necessary measures at the local level. This will help in effectively containing the pandemic. The presence of the automated system helps speed up the whole process as it can detect current outbreaks within a few days.

Last week, the research team used the coronavirus outbreak tool to confirm an outbreak in Johnson County, Iowa. The outbreak is thought to have originated from the University of Iowa. Furthermore, the tool also pointed out a few counties where outbreaks might occur. These include Wheeler County in Georgia, Whitman County in Washington, Harrisonburg County in Virginia and Monroe County in Indiana.

Analysts say the use of artificial intelligence (“AI”) to detect or deal with major disease conditions isn’t very new to many players in the biomedical field, such as Predictive Oncology (NASDAQ: POAI), so it isn’t hard to see how hugely useful the COVID-19 outbreak detection tool can be at this time.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Mike Pompeo, the U.S. Secretary of State, made it known recently that his office would be launching a program that will provide Colombia’s mining industry with the assistance needed for its development.

On the visit to Colombia, the Secretary of State revealed that the proposal would be organized by the Department of State Energy Governance and Capacity Initiative.

In a press conference that was held at the Presidential Palace last Saturday, Pompeo told Iván Duque, Colombia’s president, that American and Colombian companies could do a lot of good together, what with the welcoming investment atmosphere and good governance, fair and open relationships and transparent rules. The companies, he said, could provide good employment opportunities.

The project will begin by evaluating the mining industry of Colombia to see how it’s doing while comparing it to the mining industries of other countries in the area. After this, the next step will be to review the regulatory and legal framework of the country and figure out ways to make the framework more competitive. Additionally, the project will also assess the regulations governing the country’s copper mining sector as well as its environmental sustainability, with a focus on the best ways to store mine tailings.

Once the coronavirus pandemic ends, Colombia will be launching 33 energy and mining projects. It is expected that these projects will generate more than 50,000 employment opportunities and rake in roughly $9.6 million in terms of investments.

In a media statement, Diego Mesa, Colombia’s mining minister, said that the United States government was a tactical partner that would help enhance the sustainable recovery of the mining and energy sectors through the fulfillment of the America Grows Initiative. He added that the Colombian mining sector had been liaising with the U.S. government through USAID to help encourage the formalization of artisanal miners.

Legal Gold, which is a USAID program, helps make illegal mines legal and minimizes mercury use in gold mining operations while also calling for the implementation of zero mercury technologies.

In the fight against illegal mining, the Colombian Ministry of Mines and Energy receives support through a State Department agreement that allows land packages to be monitored when there is evidence of alluvial gold exploitation.

Coincidentally, the minister added that the U.S. Labor Department had helped Colombia to improve the working conditions in small scale gold and coal mining operations and also eradicate child labor in the mining sector.

This planned cooperation is likely to bring trickle-down benefits to the mining sector, including companies like Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR).

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

• Company awarded government grant that could total $1.45 million to develop design for production of rare earth elements
• UUUU excited to play role in effort to develop domestic sources of rare earth production
• Energy Fuels announced entry into REE sector earlier this year, ideal complement to company’s other rare earth initiatives

Energy Fuels (TSX: EFR) (NYSE American: UUUU), a leading producer of uranium in the United States, along with a team from Penn State University has been awarded a government grant for an initial amount of $150,000 to develop a design for the production of rare earth elements (“REE”) from coal-based resources (https://ibn.fm/kMbwJ). The contract was awarded by the U.S. Department of Energy (“DOE”) Office of Fossil Energy (“FE”) and the National Energy Technology Laboratory (“NETL”). If Energy Fuels is successful at the conceptual design phase, the DOE could award Energy Fuels an additional $1.3 million to complete a feasibility study.

“We are excited to have the opportunity to work with the DOE office of Fossil Energy, the National Energy Technology Laboratory, and Penn State on this important rare earth initiative,” said Energy Fuels president and CEO Mark S. Chalmers. “Energy Fuels has been carrying out substantial work over the past year to explore the potential for implementing a commercial rare earth recovery and processing program at our White Mesa Mill. This initiative to produce REOs from coal-based resources is complementary to our ongoing efforts and will potentially broaden the sources of REE feedstock available to us in the future. We also hope this project opens the door for us to work with the DOE and other agencies on future rare earth initiatives.”

The contract calls for Energy Fuels and a team of experts from Penn State to evaluate and develop a conceptual design to allow for the commercial production of mixed rare earth oxides from coal-based resources in an environmentally benign fashion. In addition, the contract also notes that DOE may award Energy Fuels a contract for the completion of a feasibility study on this initiative.

The DOE has already demonstrated the technical feasibility of extracting rare earth elements from coal and coal-based resources, but the department is looking to fast-track the advancement of commercially viable technologies to produce REEs from coal-based resources, including coal refuse, over/under burden materials, power generation ash and others.

Earlier this year, Energy Fuels announced its entry into the REE sector, noting that it believes its fully licensed and constructed White Mesa Mill could play a key role in bringing the REE supply chain back to the U.S. from China (https://ibn.fm/UEB25). The company applied for the DOE/NETL grant in June, in part because the REE minerals contained in these coal-based resources are similar to the REE minerals contained in other materials UUUU is evaluating as part of its REE program.

The contract provides initial funding for Energy Fuels and the Penn State team to complete a detailed conceptual design and flowsheet for the possible commercial operation of a facility that produces REOs from coal-based resources. Once that is complete, the DOE will determine whether to provide additional funding for the development of a feasibility study. It is also possible that the DOE could participate in the funding of a facility that performs this work.

“Rare earths are used in a host of advanced and everyday technologies, including cell phones, computers, renewable energy generation, batteries, automobiles, and military applications,” said Chalmers. “However, the U.S. does not currently have a fully integrated rare earth supply chain. Therefore, the government has made it a priority to assist in the development of domestic sources of rare earth production. With this award, we are excited to play a role in this effort, while also pursuing our other complementary rare earth initiatives. We also hope this DOE program puts Energy Fuels on the radar for other U.S. government rare earth initiatives.”

Based in Lakewood, Colorado, Energy Fuels holds three of America’s key uranium production centers: the Nichols Ranch (ISR) project in Wyoming, the Alta Mesa ISR Project in Texas and the White Mesa Mill in Utah – the only conventional uranium mill operating in the United States today. Together, these facilities have a licensed capacity of more than 11.5 million pounds of U3O8 per year. With an asset portfolio that boasts more uranium production facilities, in-ground resources, production capacity and experienced personnel than any other producer, Energy Fuels is in a unique position to maintain its position as the leading producer of uranium in an era of viable transformation of the U.S. nuclear industry.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Medical technicians, room physicians and military medics may be better equipped to treat victims of gunshot wounds, battlefield injuries and vehicular accidents thanks to a new device that is in the works. The device can evaluate the effects of hemorrhage on an individual.

The research team currently working on the device development have demonstrated that the device could accurately evaluate blood loss through the measurement of seismic vibrations in an individuals’ thoracic cavity and also by detecting the changes in an individual’s heartbeat.

Associate professor in the School of Electrical and Computer Engineering at the Georgia Institute of Technology, Omer Inan, says that the team wants to develop a device that can be placed on an individual’s chest to determine if the patient is showing any signs that could indicate aggravated performance of their cardiovascular system as a result of bleeding.

The research was published in the Science Advances journal on July 22 and included partners from various institutions such as the University of Maryland. This research was also supported by the Office of Naval Research.

As most of us may not know, blood loss may be caused by various traumas. However, hemorrhage may not present as it should which may lead to it being overlooked by doctors and first responders. People who are going through trauma normally have elevated heartrates. However, blood pressure may sometimes remain stable till blood loss reaches a critical and fatal stage, which makes it harder for first responders to treat the individual.

Having a reliable medical device that can be used to noninvasively measure an injury and help responders triage victims correctly could go a long way in saving lives.

Jacob Kimball and Jonathan Zia, who are graduate students and Inan, used animal models to study electrical signals from the heart and seismic vibrations from the thoracic cavity as the blood volume reduced gradually. The researchers’ objective was to assess the signs of the performance of the cardiovascular system that could be measured externally then compare them with the information being provided by the catheters taking blood pressure and volume measurements.

They found that a seismocardiogram was the major indicator. However, the researchers noted that as the blood volume reduced, the timing of the heart’s activity changed, thus providing another cause of a weakened cardiovascular system.

The envisioned device will combine electrical and noninvasive mechanical measures to see how critical an individual’s blood loss is. An indicator on the device would also show the general condition of the individual’s cardiovascular system and how far the system is from collapsing. In the long-term, the team would like to carry out studies on humans and see how the device performs in real time.

This potentially life-saving invention is likely to attract attention from the entire biomedical field, including companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.